PRESS RELEASES

08 March |  2021

Prilenia to Present at Upcoming Virtual Healthcare Conferences 

[Naarden, NL, 8 March 2021]  – Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announced that Dr Michael R. Hayden, MD, PhD Chief Executive Officer, will present at the following conferences in March:

  • H.C. Wainwright Global Life Sciences Conference, 9–10 March. The presentation will be available on-demand through the H.C. Wainwright conference portal. Registration Link: click here  

  • AD/PD: Alzheimer's & Parkinson's Diseases Conference, 9–14 March. The presentation will be available on-demand for registered participants in the AD/PD Meeting platform. Registration Link: click here 

About Prilenia (www.prilenia.com)

Prilenia is a clinical stage biotech startup founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders.  Prilenia raised $ 88.5 million thus far and is backed by a group of well-respected investors: Talisman, Forbion, Morningside and Sectoral and ALS Investment Fund. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.

For more information visit www.prilenia.com

Contacts:
Prilenia Therapeutics

Limor Ben Har, COO
E: info@prilenia.com

Instinctif Partners
Melanie Toyne-Sewell / Agnes Stephens / Siobhan Sanford
T: +44 (0) 207 457 2020
E: prilenia@instinctif.com

  • Twitter
  • LinkedIn